RNAC Stock Summary and Trading Ideas (Cartesian Therapeutics | NASDAQ:RNAC)

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Cartesian Therapeutics trades on the NASDAQ stock market under the symbol RNAC.

As of November 9, 2026, RNAC stock price declined to $7.15 with 206,014 million shares trading.

RNAC has a beta of 2.41, meaning it tends to be more sensitive to market movements. RNAC has a correlation of 0.10 to the broad based SPY ETF.

RNAC has a market cap of $218.10 million. This is considered a Small Cap stock.

Last quarter Cartesian Therapeutics reported $0 in Revenue and -$.38 earnings per share. This fell short of revenue expectation by $-147,144 and exceeded earnings estimates by $.63.

The top ETF exchange traded funds that RNAC belongs to (by Net Assets): VTI, IWM, JSML, VXF, IWN.

RNAC has underperformed the market in the last year with a return of -5.3%, while the SPY ETF gained +13.7%. In the last 3 month period, RNAC fell short of the market, returning -18.4%, while SPY returned -1.6%. However, in the most recent 2 weeks RNAC has outperformed the stock market by returning +15.7%, while SPY returned -0.7%.

RNAC support price is $7.17 and resistance is $7.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAC shares will trade within this expected range on the day.